Airsculpt Technologies, Inc.

Listed Company

AIRSCIK 0001870940NasdaqEmerging GrowthServices-Offices & Clinics Of Doctors Of MedicineFY ends Dec 31

Period

FY 2025

Revenue

$151.82M

Net Income

$-11.67M

Total Assets

$187.30M

Equity

$87.71M

Shares Out

70.55M

Op. Cash Flow

$3.10M

Business

Airsculpt Technologies, Inc. provides minimally invasive body contouring treatments using its proprietary, patented AirSculpt® method to remove fat, tighten skin, and sculpt targeted areas in a single awake session. It offers a suite of procedures including fat removal, fat transfer enhancements (Power BBL®, Up a Cup™, Hip Flip®), and adjunct technologies such as AirSculpt®+ and AirSculpt® Smooth for skin tightening and cellulite reduction. The company operates through accredited, spa-like patient centers and Professional Associations, with management services provided under MSAs. Services are delivered across a national and international footprint and promoted via digital marketing, social media, celebrity endorsements, virtual consults and referral channels.

Summary from filing dated 2025-03-14

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	152	180	196	169	133
Cost of service (exclusive of depreciation and amortization)	62	71	74	63	45
Selling, general and administrative	82	99	102	101	66
Depreciation and amortization	13	12	10	8	7
Loss/(gain) on disposal of long-lived assets	5	16,000	−212,000	147,000	0
Loss/(gain) on disposal of long-lived assets	2	0	0	—	—
Total operating expenses	163	182	186	173	118
(Loss)/income from operations	−12	−2	10	−5	16
Interest expense, net	6	6	6	7	—
Pre-tax net loss	−18	−8	3	−11	11
Total	−6	188,000	7	3	329,000
Net loss	−12	−8	−4	−15	11
Basic (in dollars per share)	−0.19	−0.14	−0.08	−0.26	−0.01
Diluted (in dollars per share)	−0.19	−0.14	−0.08	−0.26	−0.01
Basic (in shares)	60	58	57	56	56
Diluted (in shares)	60	58	57	56	56

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	8	8	10	10	25
Taxes receivable	1	3	2	3	0
Prepaid expenses and other current assets	6	6	4	4	4
Total current assets	15	17	16	17	29
Property and equipment, net	28	37	29	24	14
Other long-term assets	3	5	6	3	2
Right of use operating lease assets	22	29	25	24	18
Intangible assets, net	37	42	46	51	56
Goodwill	82	82	82	82	82
Total assets	187	213	204	201	201
Accounts payable	5	6	4	4	3
Accrued payroll and benefits	3	3	4	3	3
Current portion of long-term debt	5	4	2	2	850,000
Deferred revenue and patient deposits	2	1	1	2	3
Accrued and other current liabilities	5	8	3	7	4
Current operating lease liabilities	7	6	5	4	3
Total current liabilities	28	29	20	22	16
Long-term debt, net	51	65	70	81	82
Deferred tax liability, net	878,000	7	7	5	4
Long-term operating lease liabilities	20	28	23	20	15
Revolving credit funds payable	0	5	0	—	—
Other long-term liabilities	0	817,000	716,000	1	0
Total liabilities	100	135	120	130	117
Commitments and contingent liabilities (Note 9)	—	—	—	—	—
Common stock, $0.001 par value; shares authorized - 450,000,000; shares issued and outstanding - 64,455,872 and 58,369,138, respectively	64,000	58,000	57,000	56,000	56,000
Additional paid-in capital	128	108	104	86	84
Accumulated other comprehensive loss	−96,000	−687,000	−412,000	−76,000	0
Accumulated deficit	−41	−29	−20	−15	−393,000
Total stockholders' equity	88	78	83	71	84
Total liabilities and stockholders' equity	187	213	204	201	201

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Equity-based compensation	2	4	18	29	7
Non-cash interest expense; amortization of debt costs	500,000	300,000	200,000	900,000	600,000
Deferred income taxes	−6	−252,000	1	1	208,000
Cost related to closing location	2	0	0	—	—
Taxes receivable	2	−1	890,000	−3	0
Prepaid expense and other current assets	−4	−2	466,000	−5,000	−4
Other assets	7	−3	−5	−7	−1
Accounts payable	579,000	739,000	−206,000	865,000	2
Deferred revenue and patient deposits	735,000	−293,000	−896,000	−452,000	−423,000
Accrued and other liabilities	−7	9	3	8	5
Net cash used in operating activities	3	11	24	24	27
Purchases of property and equipment, net	−2	−14	−10	−13	−7
Net cash used in investing activities	−2	−14	−10	−13	−7
Payments on term loan	−14	−2	−12	−84	−838,000
Payments for debt modification	−393,000	−136,000	0	0	—
Payments on revolving credit facility	−5	5	0	—	—
Proceeds from public offerings, net	19	0	0	—	—
Distribution to member	0	0	−79,000	−1	−67
Dividends paid to shareholders	0	−252,000	−385,000	−23	0
Payment of taxes withheld through vested equity-based compensation	−56,000	−903,000	−233,000	−2	0
Other financing activity	0	−954,000	−569,000	−147,000	0
Net cash used in financing activities	−478,000	630,000	−13	−27	−5
Net decrease in cash and cash equivalents	214,000	−2	646,000	−16	15
Cash paid for interest	6	6	6	6	4
Property and equipment included in accounts payable and accrued expenses	2	2	283,000	1	255,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro